Search
Human immunoglobulin G
go.drugbank.com/drugs/DB00028ApprovedInvestigationalIVIg is used in the treatment of immunodeficiencies, as well as autoimmune and inflammatory disorders. … IVIg contains the same distribution of IgG antibody subclasses as is found in the general human population.
Nitarsone
go.drugbank.com/drugs/DB11437ExperimentalVet approvedIt is marketed as Histostat by Zoetis, a publicly traded subsidiary of Pfizer. … Nitarsone is an organoarsenic compound. It is used as an additive in poultry feed to improve weight gain and feed efficiency, while preventing blackhead disease.
Eladocagene exuparvovec
go.drugbank.com/drugs/DB16780ApprovedInvestigationalEladocagene exuparvovec is a recombinant adeno-associated virus-2 (AAV2)-based gene therapy that expresses human aromatic L-amino acid decarboxylase (AADC), and it is used to treat AADC deficiency, a fatal … [A253687] It was subsequently approved by the FDA in November 2024.[L51898,L51893]
Tofersen
go.drugbank.com/drugs/DB14782ApprovedInvestigationalTofersen is under an intrathecally administered antisense oligonucleotide targeting the mutated SOD1 gene that causes amyotrophic lateral sclerosis (ALS). … [L46133] In June of 2024, it was additionally approved by the EMA for the same indication.
Synonyms: DNA, D((2'-O-(2-METHOXYETHYL))M5RC-SP-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-SP-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))RA-SP-T-SP-A-SP-M5C-SP-A-SP-T-SP-T-SP-T-SP-M5C-SP-T-SP-A-SPCytisine
go.drugbank.com/drugs/DB09028InvestigationalRecent Phase III clinical trials using Tabex (a brand of Cytisine marketed by Sopharma AD) have shown similar efficacy to varenicline, but at a fraction of the cost. … Cytisine is a partial nicotinic acetylcholine agonist with a half-life of 4.8 hours.
Alkaline Phosphatase
go.drugbank.com/drugs/DB05768InvestigationalAlkaline Phosphatase (AP) is an oral treatment and has a very favorable side-effect profile. … AP only acts locally in the colon to reduce the continuous inflammation of the colon by endotoxin from Gram-negative bacteria and extracellular ATP in UC patients.
Zidesamtinib
go.drugbank.com/drugs/DB21623ApprovedInvestigationalanother ROS1 inhibitor has failed rather than as an alternative first choice. … [L63808,L63933] Zidesamtinib is selective for ROS1, retains activity in cells carrying the common resistance mutations, and showed antitumor activity in an intracranial model, positioning it for use after
Teduglutide
go.drugbank.com/drugs/DB08900ApprovedInvestigationalTeduglutide is a glucagon-like peptide-2 (GLP-2) analogue. It is made up of 33 amino acids and is manufactured using a strain of Escherichia coli modified by recombinant DNA technology. … The significance of this substitution is that teduglutide is longer acting than endogenous GLP-2 as it is more resistant to proteolysis from dipeptidyl peptidase-4. FDA approved on December 21, 2012.
Categories: Compounds used in a research, industrial, or household settingRauwolfia serpentina root
go.drugbank.com/drugs/DB09363Investigationalat decreased temperatures. … Reserpine is derived from Rauwolfia serpentina, and was commonly used as an antihypertensive agent in the 1950s [L1621]. Rauwolfia serpentina is also commonly referred to as _Sarpaghanda_ [A32097].
Lumefantrine co-artemether
go.drugbank.com/drugs/DB13085ApprovedInvestigationalWithdrawnWhile artemether results in rapid defervescence, parasite clearance, and clinical improvement, it also has a relatively high recrudescence rate when used as monotherapy. … Unlike artemether, lumefantrine has a slower onset of action, resulting in clearance of residual parasites and a decrease in recrudescence rate.